Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes Sells 3,000 Shares

Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes sold 3,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the sale, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Andrew Hykes also recently made the following trade(s):

• On Tuesday, October 29th, Andrew Hykes sold 3,000 shares of Inari Medical stock. The shares were sold at an average price of $50.00, for a total value of $150,000.00.

Inari Medical Stock Performance

Shares of Inari Medical stock opened at $55.45 on Friday. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of -41.07 and a beta of 0.97. The company has a fifty day moving average of $50.12 and a 200-day moving average of $48.16. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $66.61.

Institutional Trading of Inari Medical

Several institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC grew its position in Inari Medical by 7.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after acquiring an additional 348 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after acquiring an additional 435 shares during the period. Louisiana State Employees Retirement System boosted its holdings in Inari Medical by 2.4% in the second quarter. Louisiana State Employees Retirement System now owns 26,000 shares of the company’s stock valued at $1,252,000 after acquiring an additional 600 shares in the last quarter. Legato Capital Management LLC purchased a new position in Inari Medical during the 2nd quarter valued at $397,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Inari Medical by 11.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,463 shares of the company’s stock worth $696,000 after purchasing an additional 1,475 shares in the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on NARI. Oppenheimer started coverage on shares of Inari Medical in a report on Tuesday. They issued an “outperform” rating and a $75.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Canaccord Genuity Group lifted their price target on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Piper Sandler raised their target price on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 29th. Finally, Stifel Nicolaus started coverage on Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target for the company. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $61.80.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.